/Investor DB

EQT Life Sciences — 2021 Investments

4 investments dated 2021 · listed companies and verified rows first · show all

Egle Therapeuticsegle-tx.cominSeries A · Oct 2021 · $47M✓ verified

Egle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer.

Biotech

Fiorella Kotsias(Chief Scientific Officer)inBernard Vanhove(Chief Development Officer)in

BoardMichel Detheux(Chairman)in

Co-investorsBioqube VenturesFund+JDRF T1D Fund

Amolyt Pharmaamolytpharma.comSeries B · Sep 2021 · $80M

Developing therapeutic peptides targeting rare endocrine diseases (past investment).

Co-investorsAndera PartnersATEM Capital FundCTI Life Sciences Fund L.P.Kurma PartnersOctalfaSofinnova Partners+3 more

HotSpot Therapeuticshotspotthera.comin𝕏Series C · Nov 2021 · $100M

HotSpot Therapeutics develops novel biopharmaceutical products and therapeutic platforms focused on innovative biomedical technologies.

AI & Machine LearningBiotechHealthtech

BoardBruce Booth(Chairman)in

Co-investorsAtlas VentureB Capital GroupB4 CapitalMRL Ventures FundPivotal Life SciencesSofinnova Partners+2 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Visus Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.